Michelle Apperson, MD, PhD
Basic profileUniversity of California Davis Medical Center
Michelle Apperson is a Neurology physician affiliated with University of California Davis Medical Center. OpenAlex indexes 35 publications with 3,019 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4860 Y St
Acc Neurology Clinic, Suite 0100
Sacramento, CA 958172307
Telephone
916-734-3588Registry record last updated 8 Jul 2007.
Clinical trials
1 registered study on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20241 payment
- Alexion Pharmaceuticals, Inc.Program year20241 payment
- CYCLE PHARMACEUTICALS INCProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
42.3%Sphingosine 1-phosphate Receptor Modulator11.3%Fingolimod71%Gilenya18%Mayzent11%Part D<11 patientsOther immunosuppressants10.9%Vumerity38%Tecfidera31%Dimethyl Fumarate20%Bafiertam12%Part D<11 patients+ 3 more classes in this area
Nervous system
42.1%Gabapentinoids9.4%Gabapentin68%Pregabalin32%Part D≥31 patientsPotassium Channel Blocker8.8%Dalfampridine Er89%Ampyra11%Part D<11 patients+ 9 more classes in this area
Musculoskeletal
12.3%gamma-Aminobutyric Acid-ergic Agonist9.4%Baclofen100%Part D≥45 patientsCentral alpha-2 Adrenergic Agonist2.3%Tizanidine Hcl100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Primo Lara, MD
University of California Davis Medical Center
Helen Chew, MD
University of California Davis Medical Center
Ai‐Ming Yu
University of California Davis Medical Center
Burton L. Wise
University of California Davis Medical Center
Bruce Miller, MD
University of California, San Francisco (UCSF)
Bradley Boeve, MD
Mayo Clinic
Richard Lipton, MD
Albert Einstein College of Medicine
Steven Dekosky, MD
University of Florida Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”